2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1943

In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-in (Huki) Mice
Abstract Number: 1892

In Vivo Visualization of Cortical Microchannels in Metacarpal Bones in Patients with Cutaneous Psoriasis By High Resolution Peripheral Computed tomography – Detecting Cortical Pathologies before the Clinical Onset of Psoriatic-Arthritis
Abstract Number: 2188

Incidence and Mortality of Relapsing Polychondritis in the United Kingdom: A Population-Based Cohort Study
Abstract Number: 2037

Incidence and Prevalence of Myasthenia Gravis in Rheumatoid Arthritis Patients with and without Treatment Compared with the General Population
Abstract Number: 50

Incidence and Risk Factors for Osteoporotic Vertebral Fracture in Low-Income Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study
Abstract Number: 1506

Incidence of Adverse Events in Patients Treated with Intended Copies of Biologic Therapeutic Agents in Colombia and Mexico
Abstract Number: 485

Incidence of Clinical and Serological Lupus-like Disease during Anti-Tnfα-Treatment – a Two-Year Prospective Study in an Interdisciplinary Patient Cohort
Abstract Number: 1909

Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Abstract Number: 482

Incidence of Opportunistic Infections in Rheumatoid Arthritis Treated with Biological Agents
Abstract Number: 785

Incidence, Prevalence and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy
Abstract Number: 818

Incident Rheumatoid Arthritis and Risk of Mortality Among Women Followed Prospectively from 1976 to 2010 in the Nurses’ Health Study
Abstract Number: 1994

Incorporation of Musculoskeletal Ultrasound Curriculum and 6-Month Assessment of Knowledge Retention into the 2nd Year of Medical Student Training
Abstract Number: 177

Increase in Thyroid Stimulating Hormone (TSH) Levels in Patients with Gout Treated with Inhibitors of Xanthine-Oxido-Reductase
Abstract Number: 1852

Increased Cardiovascular Risk in Patients Recently Diagnosed with Psoriatic Arthritis: A Population-Based, Cohort Study
Abstract Number: 1623

Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].